Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 5,711,000	$ 9,370,000
Accounts receivable	25,000	125,000
Prepaid expenses and other current assets	619,000	521,000
Total current assets	6,355,000	10,016,000
Property and equipment, net	1,072,000	1,131,000
In process research and development	10,461,000	12,446,000
Acquired patents, net	307,000	338,000
Goodwill		7,562,000
Total assets	18,195,000	31,493,000
Current liabilities
Accounts payable and accrued expenses	1,659,000	1,044,000
Deferred revenue		245,000
Accrued compensation	895,000	728,000
Dividends payable	38,000	368,000
Insurance premium liability	185,000
Notes payable (Note 8)	803,000
Total current liabilities	3,580,000	2,385,000
Derivative liabilities	2,443,000	1,499,000
Deferred tax liability	2,449,000	3,005,000
Total liabilities	8,472,000	6,889,000
Series B redeemable convertible preferred stock
$0.01 par value, 9,357,935 shares authorized at December 31, 2016 and 2015, respectively, no shares and 7,527,853 shares issued and outstanding at December 31, 2016 and 2015, respectively (liquidation preference of $0 and $13,383,000 at December 31, 2016 and 2015, respectively)		11,890,000
Stockholders' equity
Common stock, $0.01 par value, 670,000,000 shares authorized at December 31, 2016 and 2015, 16,488,120 and 5,883,503 shares issued and outstanding at December 31, 2016 and 2015, respectively	165,000	59,000
Additional paid-in capital	390,918,000	375,177,000
Accumulated deficit	(381,360,000)	(362,522,000)
Total stockholders' equity (deficit)	9,723,000	12,714,000
Total liabilities, Series B redeemable convertible preferred stock and stockholders' equity	$ 18,195,000	$ 31,493,000